NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.
NextCell Pharma was invited to present at the Advanced Therapies Europe conference, which will take place 5 – 7 September 2023 in Portugal. NextCell participates through CEO Mathias Svahn and CSO Lindsay Davies who will talk about NextCell's research with the cell therapy drug ProTrans for the treatment of type 1 diabetes.
– For NextCell, the conference is a very good arena to present data from our clinical trials and establish contacts with potential partners and licensees for our drug candidate ProTrans, says NextCells Pharma's CEO Mathias Svahn.
Link to Advanced Therapies Europe https://advancedtherapieseurope.phacilitate.com
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
FNCA Sweden AB is assigned as Certified Adviser, firstname.lastname@example.org.
About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).